Another hostile takeover bid in the industry – this time by Horizon Pharma plc to grab Depomed Inc. for $29.25 per share in an all-stock, tax-free deal – set Wall Street buzzing, as Horizon offered a 42 percent premium over Monday's closing price of Depomed to make a deal valued at about $3 billion.